AGR2

Across TCGA pan-cancer cohorts, AGR2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of AGR2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where AGR2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AGR2 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and PDAC are the cancer types where AGR2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AGR2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−1.063	<.001	11	view →
LUAD	Male	III,IV	+1.549	<.001	9	view →
PDAC	Female	All	+1.165	<.001	8	view →
HNSC	Male	II,III,IV	−1.122	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

AGR2–CCRCC

Open the CCRCC breakdown →